CombinatoRx Incorporated: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-25

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

CombinatoRx develops combinations of approved drugs to target multiple disease pathways to treat cancer, type 2 diabetes, rheumatoid arthritis, and other immuno-inflammatory diseases. CombinatoRx applies an innovative drug discovery approach of combination high throughput screening technology (cHTS) that can rapidly and reproducibly identify novel drugs.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    CombinatoRx is a biopharmaceutical company engaged in developing synergistic combinations of approved drugs for the treatment of immuno-inflammatory diseases, chronic pain, topical dermatoses, metabolic disease and oncology. It's product line is internally generated from its combination high throughput screening (cHTS) technology.

    CombinatoRx's total revenues increased from $0.1 million in 2004 to $13 million in 2006. Prior to 2004, the company did not record revenues.

    The table highlights CombinatoRx's absolute revenue growth of +$5 million with sales of $13 million in 2006 increasing to $18 million in 2010, growing at a CAGR of 8%.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: combinatorx 1 michael frank phase crx026 comet cole publications prednisolone

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.